Cited 33 times in
Phase II study of trastuzumab in combination with S-1 and cisplatin in the first-line treatment of human epidermal growth factor receptor HER2-positive advanced gastric cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 라선영 | - |
dc.date.accessioned | 2016-02-04T11:56:00Z | - |
dc.date.available | 2016-02-04T11:56:00Z | - |
dc.date.issued | 2015 | - |
dc.identifier.issn | 0344-5704 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/141521 | - |
dc.description.abstract | PURPOSE: The use of trastuzumab, a monoclonal antibody targeting the HER2 protein, in combination with 5-fluorouracil/platinum-based chemotherapy improves survival in patients with HER2-positive advanced gastric cancer. In addition, TS-one (S-1)/platinum is also used as a standard of care in Asian countries. However, little is known about the combination of S-1/cisplatin chemotherapy and trastuzumab in patients with HER2-positive advanced gastric/gastroesophageal junction (GEJ) cancer. METHODS: We conducted a single-arm, two-stage, open-label, multicenter phase II study. Trastuzumab was administered intravenously on day 1 of the first cycle at 8 mg/kg and 6 mg/kg on day 1 of subsequent cycles. Cisplatin was administered intravenously at 60 mg/m(2) on day 1 of each cycle after trastuzumab. S-1 was administered orally [based on body surface area (BSA)] twice a day for 14 days in a 3-weekly cycle. Patients with BSA of <1.25 received a total of 80 mg of S-1, those with BSA ≥1.5 received 120 mg, and the remaining received 100 mg daily in two divided doses. RESULTS: All evaluable patients experienced tumor reduction during the trial. The primary end point (overall survival rate) was 59.3 %, with a clinical benefit rate of 66.7 %. Median progression-free survival was 7.4 months; 62.6 % patients were free from disease progression at 6 months. Median overall survival was 14.6 months, and the median time to treatment failure was 6.0 months. CONCLUSION: The combination of trastuzumab with S-1 and cisplatin demonstrated good activity, was generally well tolerated, and is a feasible treatment option in the first-line treatment of HER2-positive advanced gastric/GEJ cancers. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 397~408 | - |
dc.relation.isPartOf | CANCER CHEMOTHERAPY AND PHARMACOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.title | Phase II study of trastuzumab in combination with S-1 and cisplatin in the first-line treatment of human epidermal growth factor receptor HER2-positive advanced gastric cancer | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Clarinda Chua | - |
dc.contributor.googleauthor | Iain Beehuat Tan | - |
dc.contributor.googleauthor | Yasuhide Yamada | - |
dc.contributor.googleauthor | Sun Young Rha | - |
dc.contributor.googleauthor | Wei Peng Yong | - |
dc.contributor.googleauthor | Whee Sze Ong | - |
dc.contributor.googleauthor | Chee Kian Tham | - |
dc.contributor.googleauthor | Matthew Ng | - |
dc.contributor.googleauthor | David W. M. Tai | - |
dc.contributor.googleauthor | Satoru Iwasa | - |
dc.contributor.googleauthor | Hwee Yong Lim | - |
dc.contributor.googleauthor | Su-Pin Choo | - |
dc.identifier.doi | 10.1007/s00280-015-2811-y | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A01316 | - |
dc.relation.journalcode | J00437 | - |
dc.identifier.eissn | 1432-0843 | - |
dc.identifier.url | http://link.springer.com/article/10.1007%2Fs00280-015-2811-y | - |
dc.subject.keyword | Gastric cancer | - |
dc.subject.keyword | HER2 | - |
dc.subject.keyword | Trastuzumab | - |
dc.subject.keyword | HER2-positive gastric | - |
dc.subject.keyword | Gastroesophageal junction (GEJ) cancers | - |
dc.subject.keyword | TS-one (S-1) | - |
dc.subject.keyword | Cisplatin | - |
dc.contributor.alternativeName | Rha, Sun Young | - |
dc.contributor.affiliatedAuthor | Rha, Sun Young | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 76 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 397 | - |
dc.citation.endPage | 408 | - |
dc.identifier.bibliographicCitation | CANCER CHEMOTHERAPY AND PHARMACOLOGY, Vol.76(2) : 397-408, 2015 | - |
dc.identifier.rimsid | 30697 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.